InCharge HEALTHCARE 2021 Alabama School of Law in Tuscaloosa, Alabama. He has over twenty years of healthcare industry experience with legal and management responsibilities in hospitals, medical practices and ambulatory surgery center settings. He moved to Memphis in 2006 to serve as Administrator of Eye Specialty Group and Ridge Lake Ambulatory Surgery Center. In 2015, he assumed the role as CEO of Provident Practice Management Services. Brown is a Certified Ophthalmic Executive and his professional memberships include the American Academy of Ophthalmic Administrators Medical Group Management Association and the Alabama State Bar Association.
Partner Waller Lansden Dortch & Davis, LLP 1715 Aaron Brenner Drive Memphis, TN 38120 901-288-1651
ence” in 2017. She is also ranked in Healthcare by Mid-South Super Lawyers ®. She serves as a member of the Advisory Board of the Institute for Health Law & Policy at the University of Memphis Cecil C. Humphreys School of Law and the Common Table Health Alliance.
Burke is an accomplished healthcare attorney providing special regulatory counsel to private equity companies, hospitals, physicians, medical device companies and other healthcare clients on a wide range of complex regulatory/ compliance, operations and transactional issues. She is a prior Chair of the Tennessee Bar Association Health Law Section and was named a Fellow of the Nashville Health Care Council in 2016. Burke has been consistently recognized by Best Lawyers for the past decade, including 2012’s “Lawyer of the Year” in healthcare law for the Memphis and West Tennessee area and as a “Woman of Influ-
Principal/CEO Clearly MD 8110 North Brother Blvd Memphis, TN 38133 901-373-8949 clearlymd.com
Having managed medical practices for over 30 years, Burns currently serves as owner and CEO for ClearlyMD Practice Solutions and is responsible for the development and management of Memphis’ largest women’s health practice, Memphis Obstetrics and Gynecological Association, PC (MOGA). A graduate of Memphis State University, (now University
Does your patient have multiple sclerosis spasticity? CONSIDER OUR STUDY TESTING AN ORAL SPRAY FOR SPASTICITY IN PATIENTS WITH MULTIPLE SCLEROSIS. The RELEASE MSS3 study is currently enrolling patients who: • Are at least 18 years old • Were diagnosed with multiple sclerosis (MS) more than a year ago • Have tried at least 1 oral antispasticity therapy which was either oral baclofen or oral tizanidine • Are on a stable optimized dose of oral antispasticity drug(s), but continue to have muscle spasms If you are eligible and choose to participate in the RELEASE MSS3 study, it will last 4-5 months and will require 7 visits to the research clinic. The study drug, clinic visits, laboratory tests, and study procedures will be provided at no cost. You may also be compensated for your study-related travel expenses. Date of Preparation: September 2019 VV-MED-07558 GWSP18023 - Poster - Global - English - 18-Jun-2020 - Version 2.0
For more information, please contact:
Neurology Clinic, PC 8000 Centerview Pkwy, Ste 500 Cordova, TN 38018 • 901-747-1111 email@example.com
Materials prepared by GW Pharmaceuticals/Greenwich Biosciences
Memphis Medical News 13